STOCK TITAN
  1. Home
  2. Sec-filings
  3. SYRE
  4. [Form 4] Spyre Therapeutics, Inc. Insider Trading Activity

Spyre Therapeutics, Inc. reported $0 in revenue and a $155.2M net loss for fiscal 2025. See the full SYRE financial statements: income statement, balance sheet, cash flow and ratios, each column linked to its SEC filing.

Spyre CMO exercises options, sells 8,334 shares

Spyre Therapeutics, Inc. Chief Medical Officer Sheldon Sloan exercised options to acquire 8,334 shares of common stock at an exercise price of $27.46 per share, then sold the same 8,334 shares in open-market transactions.

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Spyre Therapeutics, Inc. Chief Medical Officer Sheldon Sloan exercised options to acquire 8,334 shares of common stock at an exercise price of $27.46 per share, then sold the same 8,334 shares in open-market transactions.

The sales occurred on July 1, 2026 at weighted average prices of $87.52 and $88.34 per share, with individual trades ranging from $87.03 to $88.95, pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on June 20, 2025. Following these transactions, Sloan reported no directly held common shares and 305,000 stock options outstanding, part of an option grant for 400,000 shares scheduled to fully vest over four years and expiring on October 1, 2034.

Positive

  • None.

Negative

  • None.
Insider Sloan Sheldon
Role Chief Medical Officer
Sold 8,334 shs ($731K)
Approx. gross sale proceeds $731K
Approx. exercise cost $229K
Approx. pre-tax spread $502K
Type Security Shares Price Value
Exercise Stock Option (Right to Buy) 8,334 $0.00 $0.00
Exercise Common Stock 8,334 $27.46 $229K
Sale Common Stock 6,500 $87.52 $569K
Sale Common Stock 1,834 $88.34 $162K
Holdings After Transaction: Stock Option (Right to Buy) — 305,000 contracts (Direct); Common Stock — 0 shares (Direct)
Footnotes (4)
  1. F1. This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025.
  2. F2. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $87.03 to $87.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range.
  3. F3. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $88.03 to $88.95, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
  4. F4. This option represents the right to purchase 400,000 shares of the Issuer's common stock, one quarter of which vested and became exercisable on October 1, 2025, with the remaining three quarters vesting in monthly installments over the following three years, subject to the Reporting Person's continued employment with the Issuer.
Shares sold 8,334 shares Common stock sold in open-market transactions on July 1, 2026
Sale price (weighted average) $87.52/share and $88.34/share Two reported weighted average sale prices for common stock
Sale price ranges $87.03–$87.99 and $88.03–$88.95 Price ranges for multiple sale transactions
Option exercise price $27.46/share Exercise price for 8,334 options converted into common stock
Remaining stock options 305,000 options Options to purchase common stock held after transactions
Total option grant size 400,000 shares Underlying shares for the CMO’s stock option award
Option expiration date October 1, 2034 Expiration for the reported stock option grant
10b5-1 plan adoption date June 20, 2025 Date the pre-arranged trading plan was adopted
Rule 10b5-1 trading plan regulatory
"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025."
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average price financial
"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging..."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
Stock Option (Right to Buy) financial
"Stock Option (Right to Buy) ... represents the right to purchase 400,000 shares of the Issuer's common stock..."
vested and became exercisable financial
"one quarter of which vested and became exercisable on October 1, 2025, with the remaining three quarters vesting..."
exercise or conversion of derivative security financial
"transaction_code_description: Exercise or conversion of derivative security"

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Sloan Sheldon
(Last)(First)(Middle)
221 CRESCENT STREET, BUILDING 23
SUITE 105
(Street)
WALTHAM MASSACHUSETTS 02453
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Spyre Therapeutics, Inc. [ SYRE ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Medical Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
07/01/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock07/01/2026M(1)8,334A$27.468,334D
Common Stock07/01/2026S(1)6,500D$87.52(2)1,834D
Common Stock07/01/2026S(1)1,834D$88.34(3)0D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$27.4607/01/2026M(1)8,334 (4)10/01/2034Common Stock8,334$0305,000D
Explanation of Responses:
1. This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025.
2. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $87.03 to $87.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range.
3. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $88.03 to $88.95, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
4. This option represents the right to purchase 400,000 shares of the Issuer's common stock, one quarter of which vested and became exercisable on October 1, 2025, with the remaining three quarters vesting in monthly installments over the following three years, subject to the Reporting Person's continued employment with the Issuer.
Remarks:
/s/ Heidy King-Jones, as Attorney-in-Fact07/02/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR